The Ghost of Martin Shkreli?
Or 'why Amylyx's pricing & commercialization strategy for ALS drug RELYVRIO pushes key life science industry tensions into the spotlight'
Wah's Wonderful War Room
A strategist's journey through the healthcare industry.
Dormant Last read · last published · next check
Read 22 hours ago and current, but nothing has been published for 4 years.
Latest posts
Why Healthcare is a Squid Game
Or 'why healthcare stakeholders keep trying to punch each other in the face'
The Fog of War (for MFP)
Or 'possible futures for US price negotiation for pharmaceutical products & what you should do about it'
The $388 Billion Dollar Myth
Or 'why is it so hard to make pure-B2C / D2C in healthcare work'
The Kickstarter(s) of Biopharma
Or 'What's happening at the intersection of #web3 & life science R&D?'
So You Want To Be a Drug (and/or Medical Device) Lord
Or 'How to determine the vision for your life sciences venture'
The Minimally Viable Biopharma Infrastructure Model
Or 'why starting a biopharma company is like playing Zerg in StarCraft'
A Strategist's Personal Holiday
Or 'reflections on my career after starting my latest role'
Breaking the Ivory Tower
Or 'why cost-effectiveness models may not be cost-effective in a future healthcare marketplace'
The Canary in the Coal Mine
Or 'How Civica Rx signals rapid value erosion for incremental innovation in life sciences'